BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goutal S, Gerstenmayer M, Auvity S, Caillé F, Mériaux S, Buvat I, Larrat B, Tournier N. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib. J Control Release 2018;292:210-20. [PMID: 30415015 DOI: 10.1016/j.jconrel.2018.11.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Qiao L, Yang H, Shao X, Yin Q, Fu X, Wei Q. Research Progress on Nanoplatforms and Nanotherapeutic Strategies in Treating Glioma. Mol Pharmaceutics. [DOI: 10.1021/acs.molpharmaceut.1c00856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gandhi K, Barzegar-fallah A, Banstola A, Rizwan SB, Reynolds JNJ. Ultrasound-Mediated Blood–Brain Barrier Disruption for Drug Delivery: A Systematic Review of Protocols, Efficacy, and Safety Outcomes from Preclinical and Clinical Studies. Pharmaceutics 2022;14:833. [DOI: 10.3390/pharmaceutics14040833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Schoen S Jr, Kilinc MS, Lee H, Guo Y, Degertekin FL, Woodworth GF, Arvanitis C. Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound. Adv Drug Deliv Rev 2022;180:114043. [PMID: 34801617 DOI: 10.1016/j.addr.2021.114043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
4 Lee Y, Lee D, Park E, Jang SY, Cheon SY, Han S, Koo H. Rhamnolipid-coated W/O/W double emulsion nanoparticles for efficient delivery of doxorubicin/erlotinib and combination chemotherapy. J Nanobiotechnology 2021;19:411. [PMID: 34876140 DOI: 10.1186/s12951-021-01160-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Lin B, Du H, Fan J, Huang D, Gao F, Li J, Zhang Y, Feng G, Dai T, Du X. Radioimmunotherapy Combined With Low-Intensity Ultrasound and Microbubbles: A Potential Novel Strategy for Treatment of Solid Tumors. Front Oncol 2021;11:750741. [PMID: 34745976 DOI: 10.3389/fonc.2021.750741] [Reference Citation Analysis]
6 Hugon G, Goutal S, Dauba A, Breuil L, Larrat B, Winkeler A, Novell A, Tournier N. [18F]2-Fluoro-2-deoxy-sorbitol PET Imaging for Quantitative Monitoring of Enhanced Blood-Brain Barrier Permeability Induced by Focused Ultrasound. Pharmaceutics 2021;13:1752. [PMID: 34834167 DOI: 10.3390/pharmaceutics13111752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Griffith JI, Kim M, Bruce DJ, Peterson CD, Kitto KF, Mohammad AS, Rathi S, Fairbanks CA, Wilcox GL, Elmquist WF. Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity. J Pharmacol Exp Ther 2022;380:34-46. [PMID: 34663676 DOI: 10.1124/jpet.121.000821] [Reference Citation Analysis]
8 Tournier N, Comtat C, Lebon V, Gennisson J. Challenges and Perspectives of the Hybridization of PET with Functional MRI or Ultrasound for Neuroimaging. Neuroscience 2021;474:80-93. [DOI: 10.1016/j.neuroscience.2020.10.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zhang W, Talele S, Sarkaria JN, Elmquist WF. Changes in the vasculature of human brain tumors: Implications for treatment. Neuro Oncol 2021:noab220. [PMID: 34515316 DOI: 10.1093/neuonc/noab220] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Angeli E, Bousquet G. Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood-Brain Barrier. Pharmaceutics 2021;13:1446. [PMID: 34575525 DOI: 10.3390/pharmaceutics13091446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Breuil L, Marie S, Goutal S, Auvity S, Truillet C, Saba W, Langer O, Caillé F, Tournier N. Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice? J Cereb Blood Flow Metab 2021;:271678X211045444. [PMID: 34496661 DOI: 10.1177/0271678X211045444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Asif M, Usman M, Ayub S, Farhat S, Huma Z, Ahmed J, Kamal MA, Hussein D, Javed A, Khan I. Role of ATP-Binding Cassette Transporter Proteins in CNS Tumors: Resistance- Based Perspectives and Clinical Updates. Curr Pharm Des 2020;26:4747-63. [PMID: 32091329 DOI: 10.2174/1381612826666200224112141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Griffith JI, Sarkaria JN, Elmquist WF. Efflux Limits Tumor Drug Delivery Despite Disrupted BBB. Trends Pharmacol Sci 2021;42:426-8. [PMID: 33736874 DOI: 10.1016/j.tips.2021.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Smith P, Ogrodnik N, Satkunarajah J, O'Reilly MA. Characterization of ultrasound-mediated delivery of trastuzumab to normal and pathologic spinal cord tissue. Sci Rep 2021;11:4412. [PMID: 33627726 DOI: 10.1038/s41598-021-83874-x] [Reference Citation Analysis]
15 de Gooijer MC, Kemper EM, Buil LCM, Çitirikkaya CH, Buckle T, Beijnen JH, van Tellingen O. ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost. Cell Rep Med 2021;2:100184. [PMID: 33521698 DOI: 10.1016/j.xcrm.2020.100184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
16 Tournier N, Goutal S, Mairinger S, Hernández-Lozano I, Filip T, Sauberer M, Caillé F, Breuil L, Stanek J, Freeman AF, Novarino G, Truillet C, Wanek T, Langer O. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib. J Cereb Blood Flow Metab 2021;41:1634-46. [PMID: 33081568 DOI: 10.1177/0271678X20965500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, Adhikaree J, Tinsley CJ, Pockley AG, McArdle SEB. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment. Front Immunol 2020;11:582106. [PMID: 33178210 DOI: 10.3389/fimmu.2020.582106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
18 Tran VL, Novell A, Tournier N, Gerstenmayer M, Schweitzer-Chaput A, Mateos C, Jego B, Bouleau A, Nozach H, Winkeler A, Kuhnast B, Larrat B, Truillet C. Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: An immunoPET study using 89Zr-cetuximab. J Control Release 2020;328:304-12. [PMID: 32860928 DOI: 10.1016/j.jconrel.2020.08.047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
19 Arif WM, Elsinga PH, Gasca-salas C, Versluis M, Martínez-fernández R, Dierckx RA, Borra RJ, Luurtsema G. Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography. Journal of Controlled Release 2020;324:303-16. [DOI: 10.1016/j.jconrel.2020.05.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
20 Aparicio-blanco J, Sanz-arriazu L, Lorenzoni R, Blanco-prieto MJ. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy. International Journal of Pharmaceutics 2020;581:119283. [DOI: 10.1016/j.ijpharm.2020.119283] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
21 Kooiman K, Roovers S, Langeveld SAG, Kleven RT, Dewitte H, O'Reilly MA, Escoffre JM, Bouakaz A, Verweij MD, Hynynen K, Lentacker I, Stride E, Holland CK. Ultrasound-Responsive Cavitation Nuclei for Therapy and Drug Delivery. Ultrasound Med Biol 2020;46:1296-325. [PMID: 32165014 DOI: 10.1016/j.ultrasmedbio.2020.01.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 75] [Article Influence: 22.0] [Reference Citation Analysis]
22 Gomez-Zepeda D, Taghi M, Scherrmann JM, Decleves X, Menet MC. ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas. Pharmaceutics 2019;12:E20. [PMID: 31878061 DOI: 10.3390/pharmaceutics12010020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
23 Wulkersdorfer B, Bauer M, Karch R, Stefanits H, Philippe C, Weber M, Czech T, Menet MC, Declèves X, Hainfellner JA, Preusser M, Hacker M, Zeitlinger M, Müller M, Langer O. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. EJNMMI Res 2019;9:110. [PMID: 31832814 DOI: 10.1186/s13550-019-0581-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Karbownik A, Sobańska K, Płotek W, Grabowski T, Klupczynska A, Plewa S, Grześkowiak E, Szałek E. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. Invest New Drugs 2020;38:574-83. [PMID: 31177402 DOI: 10.1007/s10637-019-00806-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
25 Gray KM, Katz DB, Brown EG, Stroka KM. Quantitative Phenotyping of Cell-Cell Junctions to Evaluate ZO-1 Presentation in Brain Endothelial Cells. Ann Biomed Eng 2019;47:1675-87. [PMID: 30993538 DOI: 10.1007/s10439-019-02266-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]